PARP Inhibitors: From Research to Practice Webcast Series (2021)
PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion.
Course #1: PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will update urologists and the urologic care team on the latest developments in PARPi treatments and advanced prostate cancer.
Course #2: PARP Inhibitors: Assessing the Clinical Trial Landscape will update urologists and the urologic care team on the on-going clinical trials related to PARPi and advanced prostate cancer.
Course #3: Best Practices in Advanced Prostate Cancer Care in the Community will highlight best practices in the care of advanced prostate cancer patients in the community setting, including the clinical coordination of care, shared decision making, and the more prominent role of telemedicine.
This educational series is supported by independent educational grants from:
- Nurse Practitioner
- Physician Assistant
Upon completion of this activity, participants will be able to:
PARP INHIBITORS: ASSESSING THE RAPIDLY EVOLVING TREATMENT LANDSCAPE
- Review recommended criteria for genetic testing of prostate cancer patients, currently available gene panels, and options for testing these men.
- Explain the importance of testing for germline mutations and their implication for cascade testing, other personal cancer screening (i.e. male breast cancer), as well as utilizing novel targeted therapies such as PARP inhibitors alone or in combination with alternate modalities.
- Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening and surveillance and or management options.
PARP INHIBITORS: ASSESSING THE CLINICAL TRIAL LANDSCAPE
- Describe the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition.
- Discuss the current clinical trials associated with PARP inhibitors.
- Describe the patient populations associated with each trial.
- State the clinical outcomes for each trial.
PARP INHIBITORS: BEST PRACTICES IN ADVANCED PROSTATE CANCER CARE IN THE COMMUNITY
- Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice.
- Identify opportunities for shared care and team-based approaches of patients with advanced prostate cancer.
- Discuss the impact of shared-decision making on patient and on patient-clinician communication.
- Describe how telemedicine can be successfully incorporated into the care continuum of patients with advanced prostate cancer.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by viewing the webcast and/or listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 3.0 hours
Release Date: March, 2021
Expiration Date: April, 2022
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.